Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
300267 Hunan Er-kang Pharmaceutical
- 3.12
- +0.52+20.00%
Market Closed Apr 24 15:00 CST
6.44BMarket Cap-18.46P/E (TTM)
3.12High2.60Low1.29MlotVolume2.60Open2.60Pre Close380.79MTurnover9.08%Turnover RatioLossP/E (Static)2.06BShares3.8852wk High1.44P/B4.44BFloat Cap2.0352wk Low3.12Limit Up1.42BShs Float23.06Historical High2.08Limit Down20.00%Amplitude1.20Historical Low--Dividend TTM2.95Avg Price671.20KlotAsk--Div YieldTTM100Lot Size573.71KlotBid
Hunan Er-kang Pharmaceutical Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 28.19%353.55M | -36.09%1.14B | -40.89%854.29M | -40.83%621.35M | -49.57%275.79M | -4.67%1.78B | 9.71%1.45B | 20.63%1.05B | 28.28%546.93M | -16.32%1.87B |
| Operating revenue | 28.19%353.55M | -36.09%1.14B | -40.89%854.29M | -40.83%621.35M | -49.57%275.79M | -4.67%1.78B | 9.71%1.45B | 20.63%1.05B | 28.28%546.93M | -16.32%1.87B |
| Other operating revenue | ---- | -32.07%11.38M | ---- | -65.11%6.6M | ---- | 57.61%16.76M | ---- | 589.50%18.91M | ---- | 65.29%10.63M |
| Total operating cost | 17.25%338.07M | -35.99%1.21B | -38.74%893.55M | -39.40%626.82M | -45.10%288.33M | 0.76%1.9B | 12.14%1.46B | 21.91%1.03B | 28.88%525.22M | -14.46%1.88B |
| Operating cost | 35.03%261.15M | -41.79%825.96M | -45.95%589.96M | -44.92%432.64M | -54.28%193.4M | -2.47%1.42B | 7.71%1.09B | 19.86%785.44M | 33.16%423M | -15.09%1.45B |
| Operating tax surcharges | -21.80%3.49M | 19.73%16.67M | -12.73%12.55M | -13.56%9.03M | 28.33%4.47M | 16.12%13.92M | 80.83%14.38M | 106.68%10.45M | 65.03%3.48M | -6.47%11.99M |
| Operating expense | -67.97%8.13M | -28.05%99.64M | -18.64%72.76M | -28.73%48.12M | 13.94%25.38M | 23.39%138.5M | 31.72%89.43M | 70.65%67.52M | 47.73%22.27M | -4.77%112.24M |
| Administration expense | -5.64%54.19M | -15.46%226.03M | -15.04%186.07M | -18.32%117.47M | -10.30%57.43M | 10.71%267.38M | 29.13%219.01M | 15.03%143.82M | 5.69%64.02M | -19.97%241.51M |
| Financial expense | 198.41%1.18M | 203.88%290.11K | -154.69%-1.9M | -140.39%-1.64M | -128.84%-1.2M | -99.28%95.47K | -63.16%3.47M | 32.37%4.05M | 43.98%4.15M | 155.01%13.21M |
| -Interest expense (Financial expense) | -27.41%2.73M | 36.61%9.33M | 49.47%8.26M | 37.17%6.26M | 19.86%3.76M | 24.15%6.83M | 80.93%5.53M | 153.11%4.57M | 97.08%3.14M | -40.76%5.5M |
| -Interest Income (Financial expense) | 42.06%-933.39K | -14.77%-4.73M | -19.01%-3.81M | -96.71%-2.93M | -149.84%-1.61M | -67.27%-4.13M | -104.01%-3.2M | -55.78%-1.49M | -52.87%-644.77K | 25.42%-2.47M |
| Research and development | 12.25%9.94M | -21.36%45.17M | -16.45%34.12M | -7.83%21.2M | 6.78%8.85M | 19.30%57.44M | 25.98%40.83M | 12.67%23M | -10.06%8.29M | -1.78%48.15M |
| Credit Impairment Loss | 899.48%5.67M | 100.29%70.43K | -91.88%776.62K | -76.93%2.22M | -88.86%567.4K | -260.58%-24.26M | 226.96%9.56M | 286.60%9.64M | 258.02%5.1M | -160.46%-6.73M |
| Asset Impairment Loss | -113.65%-181.35K | -165.47%-261.21M | -207.10%-339.14K | 65.32%849.38K | 111.78%1.33M | -1,931.02%-98.39M | -95.47%316.66K | -87.16%513.79K | -70.98%627.34K | 99.46%-4.84M |
| Other net revenue | -19.64%10.75M | -216.78%-296.45M | -61.36%18.96M | -47.41%17.21M | 579.83%13.38M | -470.71%-93.58M | 70.38%49.08M | 79.34%32.71M | -219.56%-2.79M | 102.96%25.24M |
| Fair value change income | ---- | 102.89%419.8K | 102.14%302.8K | 109.46%419.8K | 104.29%563K | -202.97%-14.54M | -178.57%-14.12M | -164.30%-4.44M | ---13.14M | --14.12M |
| Invest income | 715.11%2.66M | -1,121.93%-55.83M | -93.69%1.2M | 1,165.14%935.16K | 140.49%326.47K | 16.26%5.46M | 542.67%18.99M | -101.43%-87.8K | 25.06%-806.29K | -72.90%4.7M |
| -Including: Investment income associates | 97.90%-6.91K | -158.76%-48.49M | 95.07%-701.52K | 95.81%-571.66K | 97.55%-328.23K | -160.61%-18.74M | -133.05%-14.23M | -410.35%-13.65M | -787.90%-13.37M | 29.30%-7.19M |
| Asset deal income | ---42.8K | -97.75%198.25K | -98.63%172.8K | ---- | ---- | 16,436.04%8.8M | 23,580.90%12.61M | 627,239.48%12.34M | ---- | -77.10%53.24K |
| Other revenue | -75.04%2.64M | -32.18%19.9M | -22.42%16.85M | -13.36%12.78M | 94.97%10.59M | 63.47%29.34M | 159.47%21.72M | 131.89%14.75M | 21.55%5.43M | -5.07%17.95M |
| Operating profit | 3,026.76%26.23M | -79.28%-370.61M | -156.68%-20.3M | -75.85%11.73M | -95.57%838.83K | -1,600.20%-206.73M | -21.31%35.82M | 20.30%48.6M | -10.61%18.92M | 101.68%13.78M |
| Add:Non operating Income | 1,187.30%479.84K | -94.66%831.28K | -94.08%348.99K | -93.83%328.56K | -99.11%37.27K | 195.61%15.56M | 18.26%5.9M | 197.45%5.33M | 615.69%4.17M | 267.93%5.26M |
| Less:Non operating expense | -5.35%121.25K | 136.22%18.34M | 821.31%3.75M | 1,227.66%3.43M | -94.25%128.1K | 359.82%7.76M | -71.12%406.7K | -77.12%258.23K | 58,329.98%2.23M | -94.11%1.69M |
| Total profit | 3,454.38%26.59M | -95.10%-388.12M | -157.37%-23.7M | -83.91%8.63M | -96.41%748K | -1,246.31%-198.93M | -15.86%41.31M | 30.71%53.67M | -4.05%20.86M | 102.05%17.35M |
| Less:Income tax cost | 155.86%2.64M | -80.33%4.51M | -81.59%3.19M | -81.70%2.3M | 154.30%1.03M | 216.22%22.92M | -7.73%17.34M | -9.81%12.55M | -79.22%406.5K | 58.52%-19.72M |
| Net profit | 8,480.10%23.94M | -76.98%-392.63M | -212.22%-26.89M | -84.59%6.34M | -101.40%-285.7K | -698.36%-221.85M | -20.90%23.96M | 51.47%41.12M | 3.39%20.46M | 104.64%37.08M |
| Net profit from continuing operation | 8,480.10%23.94M | -76.98%-392.63M | -212.22%-26.89M | -84.59%6.34M | -101.40%-285.7K | -698.36%-221.85M | -20.90%23.96M | 51.47%41.12M | 3.39%20.46M | 104.64%37.08M |
| Less:Minority Profit | -30.85%-4.17M | 27.42%-19.26M | 91.17%-1.42M | 100.35%38.18K | 43.32%-3.19M | -199.18%-26.53M | -167.70%-16.11M | -268.12%-10.83M | -104.63%-5.62M | -26.12%-8.87M |
| Net profit of parent company owners | 868.91%28.11M | -91.16%-373.37M | -163.55%-25.47M | -87.87%6.3M | -88.87%2.9M | -525.12%-195.32M | 10.36%40.07M | 72.66%51.95M | 15.73%26.08M | 105.81%45.94M |
| Earning per share | ||||||||||
| Basic earning per share | 871.43%0.0136 | -91.13%-0.181 | -163.40%-0.0123 | -87.70%0.0031 | -88.89%0.0014 | -524.66%-0.0947 | 10.23%0.0194 | 72.60%0.0252 | 15.60%0.0126 | 105.81%0.0223 |
| Diluted earning per share | 871.43%0.0136 | -91.13%-0.181 | -163.40%-0.0123 | -87.70%0.0031 | -88.89%0.0014 | -524.66%-0.0947 | 10.23%0.0194 | 72.60%0.0252 | 15.60%0.0126 | 105.81%0.0223 |
| Other composite income | 65.96%-11.55M | -153.53%-15.46M | -257.82%-85.01M | -160.36%-38.77M | -48.74%-33.94M | -80.64%28.89M | -70.52%53.87M | -25.70%64.23M | -245.22%-22.82M | 464.71%149.22M |
| Other composite income of parent company owners | 66.22%-11.47M | -154.15%-15.52M | -258.85%-84.98M | -160.85%-38.8M | -50.34%-33.95M | -80.62%28.66M | -70.43%53.49M | -25.51%63.76M | -244.76%-22.58M | 464.61%147.88M |
| Other composite income of minority owners | -702.52%-82.74K | -75.62%55.31K | -109.44%-35.05K | -92.65%34.03K | 105.86%13.73K | -82.96%226.81K | -79.40%371.35K | -44.92%462.99K | -297.14%-234.35K | 477.07%1.33M |
| Total composite income | 136.21%12.39M | -111.49%-408.09M | -243.78%-111.9M | -130.78%-32.43M | -1,349.71%-34.22M | -203.58%-192.96M | -63.46%77.83M | -7.26%105.35M | -117.92%-2.36M | 122.20%186.29M |
| Total composite income of parent company owners | 153.61%16.64M | -133.34%-388.89M | -218.04%-110.45M | -128.09%-32.5M | -987.80%-31.05M | -185.98%-166.66M | -56.93%93.57M | 0.02%115.72M | -78.12%3.5M | 123.30%193.83M |
| Total composite income of minority owners | -34.03%-4.25M | 27.01%-19.2M | 90.74%-1.46M | 100.70%72.21K | 45.83%-3.17M | -249.02%-26.3M | -273.35%-15.74M | -393.30%-10.37M | -108.68%-5.86M | -2.06%-7.54M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs